Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp WT (BCTXW)

Briacell Therapeutics Corp WT (BCTXW)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication....

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.VN : 10.600 (-3.81%)
BCT.TO : 7.68 (-4.71%)

Barchart Exclusives

Michael Burry's Top 4 Stocks at Q1 End Look Like Good Value Now
Michael Burry's hedge fund Scion Asset Management disclosed its top 4 long stock holdings at the end of Q1. Most fell during Q1 but now these stocks look like good value for investors to piggyback on. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar